Microscopic Polyangiitis Market

Market Overview:

The 7 major microscopic polyangiitis markets reached a value of USD 31.6 Million in ​2024​. Looking forward, IMARC Group expects the 7MM to reach USD 62.7 Million by ​2035​, exhibiting a growth rate (CAGR) of 6.48% during 2025-2035.

The microscopic polyangiitis market has been comprehensively analyzed in IMARC's new report titled "Microscopic Polyangiitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Microscopic polyangiitis (MPA) is a disorder characterized by the inflammation of small blood vessels. It is an uncommon form of vasculitis. The condition can damage blood vessels and cause difficulties in several organs throughout the body. MPA typically affects persons in their 50s and 60s, although it can occur at any age. Some common symptoms of the ailment include leg swelling and dark-colored urine from kidney problems, skin bumps and spots, weight loss, tingling or numbness due to nerve damage, fever, tiredness, weakness, aches in joints or muscles, cough, shortness of breath, sinus problems, etc. Patients might also experience ear and eye problems, such as pain and visual disturbance. A diagnosis of MPA is primarily made through a combination of detailed patient history, blood tests, and physical examination. The healthcare professional may also use imaging tests, such as X-rays, computed tomography (CT), or magnetic resonance (MR) scans, which can show abnormalities in affected areas such as the lungs. Furthermore, a biopsy of an affected area is often performed to confirm the presence of vasculitis.

The escalating prevalence of autoimmune disease, where the body's defense system attacks healthy tissue, is primarily driving the microscopic polyangiitis market. In addition to this, the inflating utilization of immunosuppressants, such as cyclophosphamide and methotrexate, which act by reducing the body's overactive immune system that leads to inflammation and damage to small blood vessels, thereby controlling the disease and preventing relapses is also creating a positive outlook for the market. Moreover, the widespread adoption of plasmapheresis procedure to selectively remove harmful substances, including antibodies and immune complexes, from the plasma and replace them with a replacement fluid is further bolstering the market growth. Apart from this, the emerging popularity of Janus Kinase (JAK) inhibitors that target JAK-STAT signaling pathways to reduce pro-inflammatory cytokine production is acting as another significant growth-inducing factor. Furthermore, the rising application of mesenchymal stem cell therapy (MSCT), since it aims to reset and modulate the immune system by suppressing the inflammatory cascade, reducing apoptosis, recruiting cells, and stimulating the regeneration of tissues, is expected to drive the microscopic polyangiitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the microscopic polyangiitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for microscopic polyangiitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the microscopic polyangiitis market in any manner.

Drugs:

TRUXIMA (rituximab-abbs) is a prescription drug used in adults to treat microscopic polyangiitis. It is a monoclonal antibody that binds to the CD20 antigen, a protein present on the surface of pre-B and mature B cells. Once attached to CD20, the drug initiates a series of events that result in B cell lysis (destruction) and depletion. TRUXIMA reduces disease-related inflammation and tissue damage by targeting and reducing B lymphocytes.

Rituxan (rituximab) is a CD20 monoclonal antibody that depletes B-cells, which play a key role in autoimmune responses. By targeting and eliminating these cells, Rituxan reduces autoantibody production and inflammation, helping to control disease activity in microscopic polyangiitis while preventing further damage to blood vessels and organs.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the microscopic polyangiitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the microscopic polyangiitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current microscopic polyangiitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the microscopic polyangiitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the microscopic polyangiitis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the microscopic polyangiitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of microscopic polyangiitis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of microscopic polyangiitis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of microscopic polyangiitis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with microscopic polyangiitis across the seven major markets?
• What is the size of the microscopic polyangiitis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of microscopic polyangiitis?
• What will be the growth rate of patients across the seven major markets?

Microscopic Polyangiitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for microscopic polyangiitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the microscopic polyangiitis market?
• What are the key regulatory events related to the microscopic polyangiitis market?
• What is the structure of clinical trial landscape by status related to the microscopic polyangiitis market?
• What is the structure of clinical trial landscape by phase related to the microscopic polyangiitis market?
• What is the structure of clinical trial landscape by route of administration related to the microscopic polyangiitis market?